Loading...
Geron Corporation
GERN•NASDAQ
Healthcare
Biotechnology
$1.10
$-0.03(-3.08%)
Geron Corporation (GERN) Company Profile & Overview
Explore Geron Corporation’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.
Geron Corporation (GERN) Company Profile & Overview
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
SectorHealthcare
IndustryBiotechnology
CEODawn Carter Bir
Contact Information
Company Facts
229 Employees
IPO DateJul 31, 1996
CountryUS
Actively Trading